Hannah Joseph Hospital Ltd FY26 Results

Hannah Joseph Hospital Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a significant jump in net profit, which increased by 55.06% to ₹11.18 crore, up from ₹7.21 crore in the previous fiscal year. Revenue from operations also saw healthy growth, rising 18.73% to ₹92.05 crore from ₹77.53 crore in FY25.

Reader Takeaway: Profit growth outpaces revenue; dividend payout signals confidence, but IPO fund deployment is key.

What just happened

The company posted its audited financial results for the fiscal year ending March 31, 2026. Key financial highlights include a revenue of ₹92.05 crore and a net profit of ₹11.18 crore. The Board of Directors recommended a final dividend of ₹2 per equity share. The auditors provided an unmodified opinion on the financial statements, and the internal auditor for FY27 was re-appointed.

Why this matters

For shareholders, the results indicate robust financial performance with substantial profit growth exceeding revenue expansion. The dividend recommendation is a positive signal about the company's profitability and cash flow management. However, the status of unutilized IPO proceeds, particularly for the Radiation Oncology Centre, remains a critical factor to monitor.

The backstory

Hannah Joseph Hospital Limited is a healthcare provider. The company had previously raised funds through an Initial Public Offer (IPO). This announcement covers its financial performance for the fiscal year 2025-26, comparing it with the prior year.

What changes now

Investors will be looking for the formal approval of the recommended dividend at the upcoming Annual General Meeting. The company's focus will likely shift towards the deployment of the unutilized IPO capital for the Radiation Oncology Centre, as noted in the filing. The re-appointment of the internal auditor ensures continuity in financial oversight.

Risks to watch

A key point to monitor is the utilization of IPO proceeds. Out of ₹42 crore raised, ₹34.47 crore remains unutilized as of March 31, 2026, primarily allocated for the Radiation Oncology Centre. While management states these funds are in fixed deposits for future use, any delays or changes in deployment plans could impact future growth.

Peer comparison

While specific peer data is not provided in the filing, the reported growth rates in revenue (+18.73%) and net profit (+55.06%) suggest a potentially strong competitive position. Investors may wish to compare these metrics against other hospitals in a similar size and service segment.

Context metrics (time-bound)

• Revenue from operations: ₹92.05 crore (FY 2026) vs. ₹77.53 crore (FY 2025).
• Profit for the year: ₹11.18 crore (FY 2026) vs. ₹7.21 crore (FY 2025).
• Basic EPS: ₹6.32 (FY 2026) vs. ₹4.32 (FY 2025).
• Total Assets: ₹133.11 crore (as at March 31, 2026).
• Total Equity: ₹97.37 crore (as at March 31, 2026).

What to track next

Investors should closely watch the progress and timeline for the establishment of the Radiation Oncology Centre and the subsequent utilization of the ₹34.27 crore earmarked for it. Monitoring future quarterly results for sustained growth and dividend payout continuation will also be crucial.